PK vs PD on the MSD Platform: Similar Technology, Different Bioanalytical Strategies

The Meso Scale Discovery (MSD) platform has become a cornerstone technology for both large molecule pharmacokinetic (PK) assays and pharmacodynamic (PD) biomarker assessments. Its electrochemiluminescence detection technology offers high sensitivity, broad dynamic range, low sample volume requirements, and multiplexing capabilities, making it well suited for a variety of bioanalytical applications.

The FDA’s recently published guidance Bioanalytical Method Validation for Biomarkers places PD biomarker assays under the same umbrella as PK assays. However, the two are designed to answer fundamentally different questions. Understanding these differences is critical when developing, validating, and implementing MSD assays throughout drug development.

The primary objective of a PK assay is to determine how much drug is present in a biological matrix over time. For monoclonal antibodies, bispecifics, fusion proteins, and other biologics, PK assays support the characterization of exposure-response relationships and generation of key parameters such as Cmax, AUC, clearance, and half-life, information that is central to a regulatory submission package.

PD biomarker assays, in contrast, seek to understand the biological effect of a therapeutic. Rather than measuring the drug itself, PD assays quantify endogenous proteins, cytokines, chemokines, soluble receptors, or other biomarkers that reflect target engagement, pathway modulation, or downstream biological activity. Information gleaned from PD assays provides evidence that supports the primary clinical end point and the treatment’s mechanism-of-action and provides exploratory endpoints that could be used in future research and development.

While both assay types may utilize MSD technology, the analytical challenges are often very different.

Measuring the Drug Versus Measuring Biology

For PK assays, the focus is generally on the accurate and specific quantification of the therapeutic molecule. Small molecule drugs can be analyzed using liquid chromatography mass-spectrometry (LC-MS) based approaches, while large molecule drugs (such as biologics and peptides) are well suited for quantification using ligand binding assays (LBA), such as MSD and ELISA, and can use LC-MS for confirmatory work. Critical considerations for MSD PK studies include reagent selection, target interference, drug tolerance, and determining whether the assay measures free drug, bound drug, or total drug. The success of a PK assay often depends on the quality and characterization of anti-idiotype reagents or target-based capture and detection strategies.

PD biomarker assays present a different challenge. The analyte of interest is frequently endogenous and may be present at low concentrations within a highly variable biological background. Unlike PK assays, where the analyte is typically well defined, biomarker assays must contend with inherent biological variability, disease-state effects, matrix interference, and sample handling considerations. This distinction means biomarker assay development can be more complex than anticipated despite using a familiar analytical platform. Small differences in assay format can significantly alter the biological species being measured and ultimately affect data interpretation.

Multiplexing: A Key Advantage for Biomarker Analysis

For PK assays, multiplexing may occasionally be useful for measuring multiple therapeutic species or related analytes, but many PK methods remain singleplex assays focused on maximizing robustness and specificity.

For PD applications, multiplexing can be transformative. Cytokine panels, inflammatory markers, pathway-specific biomarker signatures, and custom biomarker panels can often be measured simultaneously from a single sample aliquot. This not only conserves precious sample volume but can also provide a more comprehensive understanding of biological response than a single biomarker measurement alone.

In many programs, multiplex biomarker analysis allows scientists to move beyond answering “Did the drug hit the target?” to asking “How did the biological system respond?”

Validation Expectations: PK and PD Are Converging

Historically, PK assays have followed well-established bioanalytical validation expectations, including assessments of accuracy, precision, selectivity, sensitivity, dilutional linearity, stability, and robustness.

Biomarker assays have traditionally been considered more fit-for-purpose, with validation requirements tailored to the intended use of the data. However, the recent FDA guidance on Bioanalytical Method Validation for Biomarkers emphasizes that biomarker assays should be developed and validated using principles that align closely with traditional bioanalytical method validation approaches while remaining appropriate for their context of use. The guidance identifies ICH M10 bioanalytical method validation principles as the starting point for biomarker assay validation, while acknowledging that biomarker assays often require scientifically justified adaptations due to endogenous analytes and biological complexity.

The publication of the guidance document has led to extensive discussion within the bioanalysis community and reflects the increasing importance of biomarkers in regulatory decision-making and drug development programs. As biomarkers move from exploratory endpoints to critical measures of pharmacology, efficacy, and patient stratification, expectations for assay performance continue to increase. FDA’s current biomarker validation guidance specifically supports validation of biomarker concentration measurements used in IND, NDA, and BLA submissions.

Practical Lessons Learned

When developing PK assays on MSD, investing in critical reagent characterization early can significantly reduce downstream challenges. Understanding target interference and clearly defining whether the assay measures free or total drug is equally important.

For PD biomarker assays, assay performance alone is rarely sufficient. Success depends on understanding the underlying biology, selecting meaningful biomarkers, controlling preanalytical variables, and ensuring that assay sensitivity aligns with expected physiological concentrations.

Perhaps the most important lesson is that while PK assays focus on measuring the drug and its availability, PD assays focus on measuring biology and the body’s response to the drug. The platform may be identical, but the scientific questions, assay strategies, and validation considerations are fundamentally different.

Conclusion

As regulatory expectations for biomarkers continue to mature, the gap between traditional PK bioanalysis and biomarker assay validation is narrowing. The future of bioanalysis will increasingly require scientists to combine rigorous analytical performance with a deep understanding of biological context.

PK assays seek to accurately quantify therapeutic exposure. PD assays seek to understand biological response. Recognizing these differences early allows scientists to build assays that are not only analytically sound but also capable of generating meaningful data to support drug development decisions.

Emery Pharma recognizes that the MSD platform provides a versatile solution for both large molecule PK and biomarker analysis. Our successful assay development approach involves more that selecting the right technology, we align assay design with the scientific question being asked. We have significant large protein and small molecule PK and PD characterization experience.

At Emery Pharma, our MSD instrument and extensive experience in bioanalysis make us the ideal partner to take on PK and PD studies, and our strong quality system means the resulting data can be used for FDA submission. Contact us today to learn how we can help you with your drug submission pathway!